Comparative Pharmacology
Head-to-head clinical analysis: PYOPEN versus V CILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PYOPEN versus V CILLIN.
PYOPEN vs V-CILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
4 g intravenously every 4 hours.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
None Documented
None Documented
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic